A high-asymmetry bet that government-backed, patented hydrogen-based titanium recycling becomes the “Bessemer moment” that reshapes America’s titanium supply chain.
Overview
IperionX (IPX) is transitioning from an R&D-stage innovator into a commercial manufacturer positioned at the center of U.S. efforts to re-shore a domestic titanium supply chain. Operating from its Titanium Manufacturing Campus in Virginia, the company uses patented Hydrogen Assisted Metallothermic Reduction (HAMR) and Hydrogen Sintering and Phase Transformation (HSPT) technologies designed to bypass the legacy, carbon-intensive Kroll process that has dominated titanium production for decades. Today’s revenue base is still formative and split between reimbursed U.S. government development programs (notably DPA Title III and IBAS) and early commercial prototype/component orders. Commercial traction is emerging via contracts such as an ~US$11M Ford agreement and specialty components for high-end consumer/luxury applications, while defense programs remain a key qualification and volume pathway. The investment case hinges on scaling: IPX plans to expand from ~200 tpa to ~1,400 tpa by mid-2027, shifting revenue toward higher-volume powder and near-net-shape component sales. The strategic proposition rests on lower unit cost, materially lower lifecycle emissions (reported ~90% lower than plasma-atomized powders when using recycled feedstock), and national-security benefits of U.S.-based, ITAR-compliant production that reduces reliance on foreign sponge supply. Over the next 12 months, key proof points include GenX continuous production validation, Titan Project DFS timing, and evidence of an EBITDA inflection as fixed-cost absorption improves.